Citadel Advisors’s Comera Life Sciences Holdings, Inc. Common Stock CMRA Stock Holding History

Citadel Advisors’s Portfolio CMRA Stock Details CMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-17,458	Closed	-$5.57K	–	15634
2023 Q3	$5.57K	Buy	+17,458	New	+$9.21K	﹤0.01%	13380

Citadel Advisors's CMRA Position: Q4 2023 in Review

Citadel Advisors sold out of Comera Life Sciences Holdings, Inc. Common Stock (CMRA) in Q4 2023, closing a stake of 17,458 shares — an estimated $5.57K sold.

Citadel Advisors first reported a position in CMRA in Q3 2023 and held it in 1 quarter. The position peaked at $5.57K in Q3 2023. 0 funds tracked by Wall St. Rank hold CMRA as of Q4 2023.

Citadel Advisors reported no remaining Comera Life Sciences Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Citadel Advisors sold 17,458 Comera Life Sciences Holdings, Inc. Common Stock shares in Q4 2023, an estimated $5.57K.
Citadel Advisors first reported a position in Comera Life Sciences Holdings, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
Citadel Advisors's Comera Life Sciences Holdings, Inc. Common Stock position peaked at $5.57K in Q3 2023.
0 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Common Stock as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.